J9361 Efbemalenograstim alfa-vuxw - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Efbemalenograstim alfa-vuxw

Brand Name:

Ryzneuta

Strength:

0.5mg

HCPCS:

J9361

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Immunostimulant

Minor Drug Class:

Granulocyte Colony-Stimulating Factor

Oral (Y/N):

No

FDA Approval Year:

2023

FDA Discontinuation Year:

CMS Effective Date:

June 10, 2024

CMS Discontinuation Date:

Status:

In Use